ACUR Acura Pharmaceuticals Dashboard

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. Its technology platforms include AVERSION, IMPEDE, and LIMITX. The company was founded on April 10, 1935 and is headquartered in Palatine, IL.

Company profile

Ticker

ACUR

Exchange

NASDAQ

Website

acurapharm.com/

CEO

Robert Jones

Incorporated

New York

Location

Illinois

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott ...

Former names

HALSEY DRUG CO INC/NEW

SEC CIK

0000786947

Corporate docs

Articles of Incorporation & Bylaws

IRS number

110853640

ACUR stock data

S&P 500

1M 1Y 2Y 5Y

Press releases

Pro users get this 30m faster

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

26 Jul 21

PALATINE, Ill., July 26, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR) today announced an amendment to its License, Development and Commercialization Agreement ("Agreement") regarding Acura's

Acura Pharmaceuticals Announces Conversion of Debt

14 Jun 21

PALATINE, Ill., June 14, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR) today announced that Abuse Deterrent Pharma, LLC ("AD Pharma") has converted the entire principle and accrued interest of its

Acura Pharmaceuticals Provides Development Update on LTX-03

7 Jun 21

PALATINE, Ill., June 07, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR) today announced the successful completion of three NDA required registration batches of the to-be-marketed LTX-03 formulation.

Acura Pharmaceuticals Announces First Quarter Ended March 31, 2021 Financial Results

17 May 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

17 May 21

1 Aug 21

31 Dec 21

Financial summary

Financial statements Chart ACUR financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	361K	361K	361K	361K	361K	361K
Cash burn (monthly)	17.33K	70.75K	86.33K	63.25K	104.33K	114.92K
Cash used (since last report)	70.37K	287.24K	350.51K	256.79K	423.59K	466.55K
Cash remaining	290.63K	73.76K	10.49K	104.21K	-62.59K	-105.55K
Runway (months of cash)	16.8	1.0	0.1	1.6	-0.6	-0.9

Beta Read what these cash burn values mean

Recent insider trades

ACUR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 Jun 21	Schutte John	Common Stock	Conversion	Aquire C	Yes	No	0.16	42,984,375	6.88M	42,984,375
9 Jun 21	Schutte John	Convertible Promissory Note Common Stock	Conversion	Dispose C	Yes	No	0.16	-	6.88M	0
9 Jun 21	Abuse Deterrent Pharma	Common Stock	Conversion	Aquire C	No	No	0.16	42,984,375	6.88M	42,984,375
9 Jun 21	Abuse Deterrent Pharma	Convertible Promissory Note Common Stock	Conversion	Dispose C	No	No	0.16	6,877,500	1.1M	0
25 May 21	William G Skelly	RSU Common Stock	Grant	Aquire A	No	No	0	66,666	0	66,666
25 May 21	Immanuel Thangaraj	RSU Common Stock	Grant	Aquire A	No	No	0	66,666	0	66,666
25 May 21	George K Ross	RSU Common Stock	Grant	Aquire A	No	No	0	66,666	0	66,666

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

ACUR institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	2	–
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	1.03K	1.03K	–
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Lenox Wealth Advisors	780	$0	0.0%
Captrust Financial Advisors	245	$0	0.0%

Largest transactions	Shares	Bought/sold	Change
Captrust Financial Advisors	245	0	0.0%
Lenox Wealth Advisors	780	0	0.0%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • Nektar Therapeutics • Elite Pharmaceuticals • Cassava Sciences • Acelrx Pharmaceuticals • KemPharm • Perrigo

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adherence, attendant, awaiting, cardiovascular, civilian, cocaine, compliance, decided, deemed, deemphasized, delinquent, diagnosed, died, enhance, exacerbating, exceeded, fed, found, good, half, hard, heroin, Inter, intraperiod, killed, lethal, lethality, licit, nonrecurring, notified, older, OUD, owner, past, pertaining, pharmacologic, pharmacology, portfolio, quality, ready, regression, remitting, renegotiate, resolution, run, SBA, sedative, shelf, shifted, simplify, Simplifying, sought, St, stimulant, substituting, synergistic, timepoint, toxicity, toxicologic, unchanged, University, unsafe, Washington

Removed: absorption, abused, abuser, abusing, abusive, accentuate, accidently, accredited, achieve, acidity, addictive, adequate, administering, Advil, agency, agent, aggregated, aggregating, alcohol, alternative, animal, AP, assignable, attractive, August, Bayer, begin, bloodstream, borrowing, bridge, broad, capacity, capsule, care, cease, centralized, certainty, chance, Chattem, chemically, chewed, cohort, collaborative, collateral, comparing, complementary, comply, complying, comprise, conducting, confirmed, considerable, correction, DEA, defeat, defending, delivered, demand, desired, deter, deterrence, differentiate, differentiated, Dilaudid, dilutive, discount, Disease, disrupt, distinguished, diversion, domestic, downturn, economically, element, emptying, enable, enforcing, enrolled, enrollment, ETA, euphoria, evolve, exempt, expended, explore, extinguishment, extractability, fail, faster, fastest, fear, feature, fluid, forensic, fourth, functionality, grow, growing, harm, healthcare, heighten, heightened, history, hospital, Ibuprofen, illegal, imputed, inappropriately, incorporate, incorporating, induce, ingest, ingestion, initiation, injected, insufflated, intent, intention, interrupt, interruption, introduce, link, Lorcet, Lortab, manipulated, manipulating, manner, mature, Measurement, mechanism, merchandising, misused, misusing, modified, monitor, morphine, movement, MTA, naloxone, naltrexone, nation, negative, neutralize, noting, objective, offer, ongoing, operate, optimization, outcome, Oxford, OxyContin, particle, patient, perception, pH, physical, physically, pledged, predominately, premium, prescribe, prescribing, prevent, primary, prime, prioritization, problem, produced, promotable, promulgated, proportionality, prosecuting, protocol, publicity, quantified, rapidly, recent, recession, recruit, referred, reformulate, Regulation, relinquish, reluctant, represent, restrictive, retain, retention, satisfactory, scientific, sell, serviced, show, simply, simultaneously, site, sixteen, split, stability, Stocking, strategic, strategy, subgroup, Substance, suffer, surged, sustain, swallowing, syringe, syringeability, tampering, Tmax, topline, unamortized, unanticipated, understood, undisclosed, unsecured, upcoming, user, variety, vast, vein, Vicodin, vitro, washout, week, widespread, worsening

From filing 10-Q 2021 Q1